Previous 10 | Next 10 |
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), is a patient-focused, innovative, commercial-stage, global biopharmaceutical company. The company announced today that the first patient with primary immune thrombo...
Zai Lab Limited (ZLAB) Q3 2021 Earnings Conference Call November 10, 2021 08:00 ET Company Participants Billy Cho - Chief Financial Officer Samantha Du - Founder, Chairperson and Chief Executive Officer Tao Fu - Chief Strategy Officer Alan Sandler - President and Head, Global Development, Onc...
Zai Lab (NASDAQ:ZLAB): Q3 GAAP EPS of -$1.01 beats by $0.23. Revenue of $43.1M (+194.2% Y/Y) misses by $0.67M. Press Release For further details see: Zai Lab EPS beats by $0.23, misses on revenue
-- Broad Product Pipeline Expands Both Vertically and Horizontally with Three New Potential First-in-Class or Best-in-Class Medicines -- Company to Host Conference Call and Webcast on November 10, 2021, at 8:00 a.m. EST SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Nov. 09, 202...
Blueprint Medicines and Zai Lab Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater China -- Zai Lab obtains exclusive rights to develop and commercialize BLU-945 and BLU-701 in Greater China -- -- Collaboration accelerates and expands g...
-- Zai Lab obtains exclusive rights to develop and commercialize BLU-945 and BLU-701 in Greater China -- -- Collaboration accelerates and expands global development of Blueprint Medicines’ next-generation EGFR inhibitors with plans to bring clinical trials of BLU-945 and BL...
Zai Lab obtains exclusive rights to develop and commercialize KarXT in Greater China Karuna to receive upfront cash payment of $35 million, up to $152 million in potential near- and long-term development and commercial milestones and other payments, and low-double-digit to hig...
Zai Lab obtains exclusive rights to develop and commercialize KarXT in Greater China Karuna to receive upfront cash payment of $35 million, up to $152 million in potential near- and long-term development and commercial milestones and other payments, and low-double-digit to high-te...
The world-wide Covid-19 experience makes clear the international nature of healthcare protection, aggravated by 21st century advances on 20th century air travel and business globalization. China has become a pivotal figure in dealing with widespread pandemics. The nature of health as ...
SHANGHAI, SAN FRANCISCO and CAMBRIDGE, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that it will report financial results and corporate updates for the ...
News, Short Squeeze, Breakout and More Instantly...
First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study Zai Lab Limited (NASDAQ: Z...
Manuscript represents the first publication from China’s gynecology oncology field to be published in Cell Publication highlights first-time learnings about the landscape of ovarian cancer microenvironment stratified by HRD and how a PARP inhibitor perturbs it Data suggest ...
2024-07-05 18:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...